Which antidepressant is known to potentially worsen glaucoma?

Duloxetine is categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI) and is often used to treat depression and anxiety disorders. One concern with antidepressants is their potential impact on ocular health, specifically in individuals with pre-existing conditions such as glaucoma.

The connection between duloxetine and glaucoma stems from its effects on neurotransmitters that can influence intraocular pressure. While duloxetine is effective in treating depression and anxiety, its pharmacological properties may lead to an increase in intraocular pressure in susceptible individuals, potentially worsening glaucoma. This relationship highlights the importance of monitoring patients with a history of glaucoma when prescribing medications that have the potential to affect eye pressure.

In contrast, other antidepressants such as amitriptyline, venlafaxine, and bupropion have different mechanisms of action and may not carry the same risk for worsening glaucoma. Understanding these pharmacological nuances is crucial for safe prescribing practices, especially in patients with known ocular conditions.